Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries, a generic pharmaceutical company, has received the FDA approval for the company's abbreviated new drug application to market its generic version of Medicis Pharmaceutical's acne treatment Solodyn extended-release tablets, 45mg, 90mg and 135mg. Shipment of this product has commenced.
Subscribe to our email newsletter
As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
Teva is currently involved in patent litigation concerning this product in the US District Court of Delaware. A trial date has not been set.